NEW YORK, July 31 (Praxis Press) Patients with psoriasis and psoriatic arthritis have increased concentrations of tumor necrosis factor in their skin lesions and joints. Mease and colleagues studied ...
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that competition for early-line use of Amgen/Pfizer's Enbrel and ...
10 May 2005Wyeth Pharmaceuticals achieve EU and FDA approval for treating plaque psoriasis Dubai - Wyeth Pharmaceuticals today announced that ENBREL? (etanercept), a novel biologic treatment for ...
Evidence-based recommendations on etanercept (Enbrel) for treating severe psoriasis in adults. Since this guidance was published an equality consideration has been raised about the PASI instrument.
The safety of etanercept in this patient population was established through multiple pediatric trials, including a clinical study in 69 children aged 2 to 17 years with moderately to severely active ...
Dublin, June 21, 2019 (GLOBE NEWSWIRE) -- The "Plaque Psoriasis: Global Drug Forecast and Market Analysis to 2027" report has been added to ResearchAndMarkets.com's offering. "Plaque Psoriasis: Global ...
Amgen Inc., the world's biggest biotechnology company, is seeking approval to sell its Enbrel rheumatoid-arthritis drug as a treatment for psoriasis, which analysts said could nearly double the ...
The competing rheumatoid arthritis drugs of Immunex Corp. and Johnson & Johnson may offer effective new approaches to easing the chronic skin flares of psoriasis, new research shows. A study presented ...
WASHINGTON (Reuters) - U.S. Food and Drug Administration reviewers are concerned about life-threatening complications in children taking Amgen Inc's drug Enbrel for psoriasis and other conditions, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results